Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: A magnetoresistive random access memory (MRAM) device includes a first array region and a second array region on a substrate, a first magnetic tunneling junction (MTJ) on the first array region, a first top electrode on the first MTJ, a second MTJ on the second array region, and a second top electrode on the second MTJ. Preferably, the first top electrode and the second top electrode include different nitrogen to titanium (N/Ti) ratios.

Abstract: Provided herein are methods of treating a subject that include administering a therapeutically effective amount of an NLPR3 antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having a cell that has an elevated level of NLRP3 inflammasome activity and/or expression as compared to a reference level. Provided herein are methods of treating a subject, methods of selecting a treatment for a subject, methods of selecting a subject for treatment, and methods of selecting a subject for participation in a clinical study that include the administration of a therapeutically effective amount of an NLRP3 antagonist. Also provided are methods of treating a subject having resistance to an anti-TNF? agent and methods of determining the efficacy of treatment with an anti-TNF? agent. Also provided are methods of treating a subject with a combination of an NLRP3 antagonist and an anti-TNF? agent.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein.

Abstract: A method for rapidly calculating intersection over union (IOU) between a target region and a designated region in an image is used in an electronic device. The electronic device detects a target object from an image received from a monitored location, and determines a designated region, a target region, and a combined region from the image, the target region including the target object. The electronic device calculates a first area of the designated region, a second area of the target region, and a third area of the combined region, and calculates a value of IOU according to formula of SIOU=(S1+S2?S3)/S2. S1 represents the first area, S2 represents the second area, and S3 represents the third area. The electronic device issues an intrusion warning in or concerning a monitored region according to a comparison result between the value of IOU and a preset threshold.

Abstract: In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula (AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.

Abstract: An echo and near-end cross-talk (NEXT) cancellation system includes a time-domain processing module and a frequency-domain processing module. The time-domain processing module is configured to receive an unprocessed signal after an analog-to-digital conversion, remove at least one time-domain dominant component of interference from the unprocessed signal, and accordingly cancel a time-domain processed signal. The frequency-domain processing module is connected to the time-domain processing module, and configured to receive the time-domain processed signal, cancel at least one frequency-domain component of the interference from the unprocessed signal, and accordingly generate a processed signal.

Abstract: The invention discloses a parametric system for testing a capability of auditory spatial positioning and a method of providing a parametric minimum audible angle. The system includes: an host computer system calculating spatial movement data and communicating with a slave computer; a spatial movement system realizing control of any spatial position through circumferential movement, radial movement and vertical movement; a real-time three-dimensional display system built into the host computer system; an audio system randomly generates a type of audio data of a sound source and a sound source with equal-difference decibels; and a test system for matching human spatial positioning results to sound source spatial data and providing an objective evaluation. The invention further provides a method of providing a parametric minimum audible angle for a capability of auditory spatial positioning, the invention improves the control accuracy.

Abstract: The present invention provides an asymmetric EEG-based coding and decoding methods for BCIs, the BCI system includes an evoked stimulus module, an acquisition module and an EEG signal data set including a training set Xk and a testing sample Y, and an EEG signal decoding module; the evoked stimulus module sends a hybrid coding visual stimulus to subjects to evoke a specific EEG signal as required; the acquisition module obtains data information by amplifying and filtering the EEG signal so as to constitute EEG signal module; the decoding module coverts the data information into an instruction set for outputting the coding method of the present invention uses asymmetric characteristics of brain electrophysiological activity response to stimulus, combines with coding strategies such as SDMA, CDMA, FDMA and phase division multiple access coding.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.

Abstract: A method for filtering out a background audio signal includes: obtaining a first audio signal collected during playing of the background audio signal, the background audio signal being an audio signal obtained by adding watermark information to an original audio signal; separating the first audio signal to obtain the watermark information and a second audio signal without the watermark information; querying the preset correspondence according to the watermark information to obtain the original audio signal corresponding to the watermark information; and filtering out the original audio signal from the second audio signal to obtain a target audio signal.

Abstract: An image transformation method includes: obtaining identification information of an original image; converting the identification information to an identification image; performing frequency domain transformation on the original image to obtain a pixel matrix of the original image in a frequency domain space; performing matrix decomposition on the pixel matrix to obtain an image brightness matrix; converting pixel values of corresponding pixels in the image brightness matrix based on pixel values of pixels in the identification image to obtain a converted brightness matrix; and performing inverse frequency domain transformation on the converted brightness matrix to obtain a transformed image including invisible identification information, and adding the invisible identification information to the original image.

Abstract: The present invention relates to a compound represented by formula I?: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.